American Century Companies Inc. Has $69,000 Stake in aTyr Pharma, Inc. $ATYR

American Century Companies Inc. reduced its position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR - Free Report) by 74.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,703 shares of the company's stock after selling 65,409 shares during the period. American Century Companies Inc.'s holdings in aTyr Pharma were worth $69,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of ATYR. Dimensional Fund Advisors LP purchased a new position in aTyr Pharma in the 4th quarter worth about $881,000. Bank of America Corp DE acquired a new stake in shares of aTyr Pharma during the 4th quarter valued at about $330,000. Jane Street Group LLC acquired a new stake in shares of aTyr Pharma during the 4th quarter valued at about $720,000. Millennium Management LLC acquired a new stake in aTyr Pharma in the 4th quarter worth approximately $1,332,000. Finally, Raymond James Financial Inc. acquired a new stake in aTyr Pharma in the 4th quarter worth approximately $39,000. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Stock Up 14.6%

Shares of NASDAQ:ATYR traded up $0.77 during mid-day trading on Friday, reaching $6.03. 16,615,145 shares of the stock were exchanged, compared to its average volume of 4,069,044. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to-equity ratio of 0.01. The company has a market cap of $590.88 million, a P/E ratio of -7.54 and a beta of 1.01. aTyr Pharma, Inc. has a one year low of $1.67 and a one year high of $7.29. The stock's 50 day simple moving average is $5.36 and its 200-day simple moving average is $4.38.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). As a group, equities research analysts predict that aTyr Pharma, Inc. will post -0.91 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on ATYR. Jefferies Financial Group lifted their price target on aTyr Pharma from $9.00 to $17.00 and gave the stock a "buy" rating in a research report on Friday, August 22nd. HC Wainwright reiterated a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wall Street Zen lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company upped their price target on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $23.25.

aTyr Pharma Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.